Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617

Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit

 Key Statistics

Ownership: Public

Web Site: Biogen Idec, Inc. (Massachusetts)
Employees: 1700
Symbol: BIIB



NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)

Dyax Corp.  Antibody phage display

 Company News
Quintiles, Inc. (Q) And Biogen Idec, Inc. (Massachusetts) (BIIB) Announce Comprehensive Clinical Development Partnership 4/24/2014 8:02:46 AM    More...
Biogen Idec, Inc. (Massachusetts) (BIIB) First Quarter 2014 Revenues Reach $2.1 Billion Driven By Continued Strength Of MS Franchise 4/23/2014 7:23:34 AM    More...
Why People Love Working For Big Pharmas Like Biogen Idec, Inc. (Massachusetts) (BIIB), Celgene (CELG), And Gilead Sciences, Inc. (GILD) 4/18/2014 7:53:43 AM    More...
Biogen Idec, Inc. (Massachusetts) (BIIB) To Present New Clinical Data From Its Robust Neurology Portfolio At AAN Annual Meeting 4/14/2014 6:41:02 AM    More...
Biogen Idec, Inc. (Massachusetts) (BIIB) Names Adam M. Koppel As SVP And Chief Strategy Officer 4/10/2014 7:28:58 AM    More...
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014 6:42:28 AM    More...
Biogen Idec, Inc. (Massachusetts) (BIIB) To Report First Quarter 2014 Financial Results On April 23, 2014 4/1/2014 6:57:16 AM    More...
FDA Approves Biogen Idec, Inc. (Massachusetts) (BIIB)'s Hemophilia B Drug Alprolix 3/28/2014 5:26:56 PM    More...
Health Canada Approves Biogen Idec, Inc. (Massachusetts) (BIIB)'s Long-Acting ALPROLIX™ Therapy For Hemophilia B 3/24/2014 6:39:33 AM    More...
Biogen Idec, Inc. (Massachusetts) (BIIB) To Present On Best Practices For Leveraging Quality And Regulatory Compliance Management Software On Apple iPads 3/21/2014 9:15:56 AM    More...